BDTX Stock Forecast & Price Target

Black Diamond Therapeutic is a promising clinical-stage oncology company with a deep understanding of cancer genetics and a strong focus on developing MasterKey therapies targeting families of oncogenic mutations in patients with cancer. Its lead program, silevertinib, has demonstrated strong efficacy (60% cORR) and broad activity across patients with non-classical mutations, including those with brain metastases where silevertinib has shown a CNS ORR of 86%, doubling the efficacy of competitor drugs. The company has upcoming catalysts in 4Q25 and 1H26, including clinical updates, potential partnerships, and plans to discuss a registrational path forward with the FDA. With a market capitalization of only $230M, there is potential for significant value creation for BDTX shares over the next 12 months.

Black Diamond Therapeutic is facing challenges in its clinical-stage program for silevertinib, which has shown a clustering of progression events that could result in a shorter progression-free survival compared to its competitors. Additionally, its differentiated approach of targeting a broader set of non-classical mutations may not offer a better alternative for patients already responding well to osimertinib. The potential entry point into the company may seem attractive, but the company's current valuation of <$100M reflects investors' concerns about the success of silevertinib.